A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)

Cannabidiol (CBD) is an abundant non‐psychoactive phytocannabinoid in cannabis extracts which has high affinity on a series of receptors, including Type 1 cannabinoid receptor (CB1), Type 2 cannabinoid receptor (CB2), GPR55, transient receptor potential vanilloid (TRPV) and peroxisome proliferator‐a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Basic & clinical pharmacology & toxicology 2022-04, Vol.130 (4), p.439-456
Hauptverfasser:	Peng, Jiangling, Fan, Mingjie, An, Chelsea, Ni, Feng, Huang, Wendong, Luo, Jiankang
Format:	Artikel
Sprache:	eng
Schlagworte:	Analgesics Anticancer properties Antipsychotics Cannabidiol Cannabinoid CB1 receptors Cannabinoid CB2 receptors cannabinoid receptor Cannabinoids Cannabis clinical trial Clinical trials Complications COVID-19 endocannabinoid system Inflammation Neuroprotection Peroxisome proliferator-activated receptors Receptors Transient receptor potential proteins
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Cannabidiol (CBD) is an abundant non‐psychoactive phytocannabinoid in cannabis extracts which has high affinity on a series of receptors, including Type 1 cannabinoid receptor (CB1), Type 2 cannabinoid receptor (CB2), GPR55, transient receptor potential vanilloid (TRPV) and peroxisome proliferator‐activated receptor gamma (PPARγ). By modulating the activities of these receptors, CBD exhibits multiple therapeutic effects, including neuroprotective, antiepileptic, anxiolytic, antipsychotic, anti‐inflammatory, analgesic and anticancer properties. CBD could also be applied to treat or prevent COVID‐19 and its complications. Here, we provide a narrative review of CBD's applications in human diseases: from mechanism of action to clinical trials.
ISSN:	1742-7835 1742-7843
DOI:	10.1111/bcpt.13710